nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2C19—Teniposide—lymphatic system cancer	0.152	0.296	CbGbCtD
Bicalutamide—CYP2C9—Teniposide—lymphatic system cancer	0.126	0.246	CbGbCtD
Bicalutamide—CYP3A4—Cytarabine—lymphatic system cancer	0.0746	0.145	CbGbCtD
Bicalutamide—CYP3A4—Teniposide—lymphatic system cancer	0.0735	0.143	CbGbCtD
Bicalutamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0514	0.1	CbGbCtD
Bicalutamide—CYP3A4—Vincristine—lymphatic system cancer	0.0354	0.0689	CbGbCtD
Bicalutamide—Sweating—Mitoxantrone—lymphatic system cancer	0.000862	0.00177	CcSEcCtD
Bicalutamide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00086	0.00177	CcSEcCtD
Bicalutamide—Haematuria—Mitoxantrone—lymphatic system cancer	0.000858	0.00176	CcSEcCtD
Bicalutamide—Oedema peripheral—Carmustine—lymphatic system cancer	0.000856	0.00176	CcSEcCtD
Bicalutamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.000849	0.00174	CcSEcCtD
Bicalutamide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000844	0.00173	CcSEcCtD
Bicalutamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.000838	0.00172	CcSEcCtD
Bicalutamide—Visual impairment—Carmustine—lymphatic system cancer	0.000837	0.00172	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000832	0.00171	CcSEcCtD
Bicalutamide—Fatigue—Fludarabine—lymphatic system cancer	0.000831	0.00171	CcSEcCtD
Bicalutamide—Pain—Fludarabine—lymphatic system cancer	0.000824	0.00169	CcSEcCtD
Bicalutamide—Constipation—Fludarabine—lymphatic system cancer	0.000824	0.00169	CcSEcCtD
Bicalutamide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000822	0.00169	CcSEcCtD
Bicalutamide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000819	0.00168	CcSEcCtD
Bicalutamide—Urethral disorder—Vincristine—lymphatic system cancer	0.000813	0.00167	CcSEcCtD
Bicalutamide—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000812	0.00167	CcSEcCtD
Bicalutamide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000809	0.00166	CcSEcCtD
Bicalutamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.000808	0.00166	CcSEcCtD
Bicalutamide—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000807	0.00166	CcSEcCtD
Bicalutamide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000801	0.00165	CcSEcCtD
Bicalutamide—Anaemia—Bleomycin—lymphatic system cancer	0.000801	0.00165	CcSEcCtD
Bicalutamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000794	0.00163	CcSEcCtD
Bicalutamide—Asthenia—Teniposide—lymphatic system cancer	0.000787	0.00162	CcSEcCtD
Bicalutamide—Melaena—Methotrexate—lymphatic system cancer	0.000782	0.00161	CcSEcCtD
Bicalutamide—Pruritus—Teniposide—lymphatic system cancer	0.000776	0.0016	CcSEcCtD
Bicalutamide—Arrhythmia—Carmustine—lymphatic system cancer	0.000776	0.00159	CcSEcCtD
Bicalutamide—Cardiac disorder—Vincristine—lymphatic system cancer	0.000769	0.00158	CcSEcCtD
Bicalutamide—Alopecia—Carmustine—lymphatic system cancer	0.000767	0.00158	CcSEcCtD
Bicalutamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.000762	0.00157	CcSEcCtD
Bicalutamide—Mental disorder—Carmustine—lymphatic system cancer	0.000761	0.00156	CcSEcCtD
Bicalutamide—Malnutrition—Carmustine—lymphatic system cancer	0.000756	0.00155	CcSEcCtD
Bicalutamide—Cough—Bleomycin—lymphatic system cancer	0.000756	0.00155	CcSEcCtD
Bicalutamide—Angiopathy—Vincristine—lymphatic system cancer	0.000752	0.00155	CcSEcCtD
Bicalutamide—Diarrhoea—Teniposide—lymphatic system cancer	0.000751	0.00154	CcSEcCtD
Bicalutamide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000747	0.00154	CcSEcCtD
Bicalutamide—Chest pain—Bleomycin—lymphatic system cancer	0.000737	0.00152	CcSEcCtD
Bicalutamide—Myalgia—Bleomycin—lymphatic system cancer	0.000737	0.00152	CcSEcCtD
Bicalutamide—Alopecia—Vincristine—lymphatic system cancer	0.000733	0.00151	CcSEcCtD
Bicalutamide—Back pain—Carmustine—lymphatic system cancer	0.000731	0.0015	CcSEcCtD
Bicalutamide—Mental disorder—Vincristine—lymphatic system cancer	0.000726	0.00149	CcSEcCtD
Bicalutamide—Chills—Mitoxantrone—lymphatic system cancer	0.000724	0.00149	CcSEcCtD
Bicalutamide—Ecchymosis—Methotrexate—lymphatic system cancer	0.000724	0.00149	CcSEcCtD
Bicalutamide—Neoplasm—Methotrexate—lymphatic system cancer	0.000724	0.00149	CcSEcCtD
Bicalutamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000721	0.00148	CcSEcCtD
Bicalutamide—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000717	0.00147	CcSEcCtD
Bicalutamide—Alopecia—Mitoxantrone—lymphatic system cancer	0.000713	0.00147	CcSEcCtD
Bicalutamide—Confusional state—Bleomycin—lymphatic system cancer	0.000713	0.00146	CcSEcCtD
Bicalutamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00071	0.00146	CcSEcCtD
Bicalutamide—Oedema—Bleomycin—lymphatic system cancer	0.000707	0.00145	CcSEcCtD
Bicalutamide—Infection—Bleomycin—lymphatic system cancer	0.000702	0.00144	CcSEcCtD
Bicalutamide—Anaemia—Carmustine—lymphatic system cancer	0.000699	0.00144	CcSEcCtD
Bicalutamide—Back pain—Vincristine—lymphatic system cancer	0.000698	0.00143	CcSEcCtD
Bicalutamide—Vomiting—Teniposide—lymphatic system cancer	0.000697	0.00143	CcSEcCtD
Bicalutamide—Sepsis—Methotrexate—lymphatic system cancer	0.000695	0.00143	CcSEcCtD
Bicalutamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000692	0.00142	CcSEcCtD
Bicalutamide—Asthenia—Fludarabine—lymphatic system cancer	0.000692	0.00142	CcSEcCtD
Bicalutamide—Rash—Teniposide—lymphatic system cancer	0.000692	0.00142	CcSEcCtD
Bicalutamide—Dermatitis—Teniposide—lymphatic system cancer	0.000691	0.00142	CcSEcCtD
Bicalutamide—Headache—Teniposide—lymphatic system cancer	0.000687	0.00141	CcSEcCtD
Bicalutamide—Pruritus—Fludarabine—lymphatic system cancer	0.000682	0.0014	CcSEcCtD
Bicalutamide—Back pain—Mitoxantrone—lymphatic system cancer	0.00068	0.0014	CcSEcCtD
Bicalutamide—Anorexia—Bleomycin—lymphatic system cancer	0.000674	0.00138	CcSEcCtD
Bicalutamide—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000672	0.00138	CcSEcCtD
Bicalutamide—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000669	0.00137	CcSEcCtD
Bicalutamide—Anaemia—Vincristine—lymphatic system cancer	0.000667	0.00137	CcSEcCtD
Bicalutamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00066	0.00136	CcSEcCtD
Bicalutamide—Hypertension—Carmustine—lymphatic system cancer	0.000653	0.00134	CcSEcCtD
Bicalutamide—Nausea—Teniposide—lymphatic system cancer	0.000652	0.00134	CcSEcCtD
Bicalutamide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00065	0.00134	CcSEcCtD
Bicalutamide—Hepatic failure—Methotrexate—lymphatic system cancer	0.000647	0.00133	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000644	0.00132	CcSEcCtD
Bicalutamide—Myalgia—Carmustine—lymphatic system cancer	0.000644	0.00132	CcSEcCtD
Bicalutamide—Chest pain—Carmustine—lymphatic system cancer	0.000644	0.00132	CcSEcCtD
Bicalutamide—Anxiety—Carmustine—lymphatic system cancer	0.000641	0.00132	CcSEcCtD
Bicalutamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.000635	0.0013	CcSEcCtD
Bicalutamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00063	0.0013	CcSEcCtD
Bicalutamide—Hypertension—Vincristine—lymphatic system cancer	0.000623	0.00128	CcSEcCtD
Bicalutamide—Confusional state—Carmustine—lymphatic system cancer	0.000622	0.00128	CcSEcCtD
Bicalutamide—Oedema—Carmustine—lymphatic system cancer	0.000617	0.00127	CcSEcCtD
Bicalutamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000614	0.00126	CcSEcCtD
Bicalutamide—Myalgia—Vincristine—lymphatic system cancer	0.000614	0.00126	CcSEcCtD
Bicalutamide—Cough—Mitoxantrone—lymphatic system cancer	0.000613	0.00126	CcSEcCtD
Bicalutamide—Infection—Carmustine—lymphatic system cancer	0.000613	0.00126	CcSEcCtD
Bicalutamide—Vomiting—Fludarabine—lymphatic system cancer	0.000613	0.00126	CcSEcCtD
Bicalutamide—Rash—Fludarabine—lymphatic system cancer	0.000608	0.00125	CcSEcCtD
Bicalutamide—Dermatitis—Fludarabine—lymphatic system cancer	0.000607	0.00125	CcSEcCtD
Bicalutamide—Hypertension—Mitoxantrone—lymphatic system cancer	0.000607	0.00125	CcSEcCtD
Bicalutamide—Pain—Bleomycin—lymphatic system cancer	0.000604	0.00124	CcSEcCtD
Bicalutamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000604	0.00124	CcSEcCtD
Bicalutamide—Headache—Fludarabine—lymphatic system cancer	0.000604	0.00124	CcSEcCtD
Bicalutamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000598	0.00123	CcSEcCtD
Bicalutamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000598	0.00123	CcSEcCtD
Bicalutamide—Anxiety—Mitoxantrone—lymphatic system cancer	0.000596	0.00123	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000593	0.00122	CcSEcCtD
Bicalutamide—Oedema—Vincristine—lymphatic system cancer	0.000589	0.00121	CcSEcCtD
Bicalutamide—Anorexia—Carmustine—lymphatic system cancer	0.000588	0.00121	CcSEcCtD
Bicalutamide—Infection—Vincristine—lymphatic system cancer	0.000585	0.0012	CcSEcCtD
Bicalutamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000583	0.0012	CcSEcCtD
Bicalutamide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000578	0.00119	CcSEcCtD
Bicalutamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000578	0.00119	CcSEcCtD
Bicalutamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000577	0.00119	CcSEcCtD
Bicalutamide—Oedema—Mitoxantrone—lymphatic system cancer	0.000574	0.00118	CcSEcCtD
Bicalutamide—Nausea—Fludarabine—lymphatic system cancer	0.000573	0.00118	CcSEcCtD
Bicalutamide—Infection—Mitoxantrone—lymphatic system cancer	0.00057	0.00117	CcSEcCtD
Bicalutamide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000569	0.00117	CcSEcCtD
Bicalutamide—Shock—Mitoxantrone—lymphatic system cancer	0.000564	0.00116	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000562	0.00116	CcSEcCtD
Bicalutamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000562	0.00115	CcSEcCtD
Bicalutamide—Urticaria—Bleomycin—lymphatic system cancer	0.000562	0.00115	CcSEcCtD
Bicalutamide—Anorexia—Vincristine—lymphatic system cancer	0.000561	0.00115	CcSEcCtD
Bicalutamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000559	0.00115	CcSEcCtD
Bicalutamide—Insomnia—Carmustine—lymphatic system cancer	0.000558	0.00115	CcSEcCtD
Bicalutamide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000557	0.00115	CcSEcCtD
Bicalutamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000555	0.00114	CcSEcCtD
Bicalutamide—Paraesthesia—Carmustine—lymphatic system cancer	0.000554	0.00114	CcSEcCtD
Bicalutamide—Dyspnoea—Carmustine—lymphatic system cancer	0.00055	0.00113	CcSEcCtD
Bicalutamide—Somnolence—Carmustine—lymphatic system cancer	0.000549	0.00113	CcSEcCtD
Bicalutamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000547	0.00112	CcSEcCtD
Bicalutamide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000537	0.0011	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000537	0.0011	CcSEcCtD
Bicalutamide—Decreased appetite—Carmustine—lymphatic system cancer	0.000536	0.0011	CcSEcCtD
Bicalutamide—Insomnia—Vincristine—lymphatic system cancer	0.000533	0.00109	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000533	0.00109	CcSEcCtD
Bicalutamide—Paraesthesia—Vincristine—lymphatic system cancer	0.000529	0.00109	CcSEcCtD
Bicalutamide—Pain—Carmustine—lymphatic system cancer	0.000528	0.00108	CcSEcCtD
Bicalutamide—Constipation—Carmustine—lymphatic system cancer	0.000528	0.00108	CcSEcCtD
Bicalutamide—Breast disorder—Methotrexate—lymphatic system cancer	0.000525	0.00108	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000523	0.00107	CcSEcCtD
Bicalutamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000521	0.00107	CcSEcCtD
Bicalutamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000515	0.00106	CcSEcCtD
Bicalutamide—Decreased appetite—Vincristine—lymphatic system cancer	0.000512	0.00105	CcSEcCtD
Bicalutamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000511	0.00105	CcSEcCtD
Bicalutamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00051	0.00105	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000509	0.00105	CcSEcCtD
Bicalutamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000508	0.00105	CcSEcCtD
Bicalutamide—Fatigue—Vincristine—lymphatic system cancer	0.000508	0.00104	CcSEcCtD
Bicalutamide—Asthenia—Bleomycin—lymphatic system cancer	0.000507	0.00104	CcSEcCtD
Bicalutamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000505	0.00104	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000505	0.00104	CcSEcCtD
Bicalutamide—Pain—Vincristine—lymphatic system cancer	0.000504	0.00104	CcSEcCtD
Bicalutamide—Constipation—Vincristine—lymphatic system cancer	0.000504	0.00104	CcSEcCtD
Bicalutamide—Asthma—Methotrexate—lymphatic system cancer	0.000503	0.00103	CcSEcCtD
Bicalutamide—Pruritus—Bleomycin—lymphatic system cancer	0.0005	0.00103	CcSEcCtD
Bicalutamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000499	0.00102	CcSEcCtD
Bicalutamide—Eosinophilia—Methotrexate—lymphatic system cancer	0.000498	0.00102	CcSEcCtD
Bicalutamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000495	0.00102	CcSEcCtD
Bicalutamide—Pain—Mitoxantrone—lymphatic system cancer	0.000491	0.00101	CcSEcCtD
Bicalutamide—Constipation—Mitoxantrone—lymphatic system cancer	0.000491	0.00101	CcSEcCtD
Bicalutamide—Abdominal pain—Carmustine—lymphatic system cancer	0.000488	0.001	CcSEcCtD
Bicalutamide—Body temperature increased—Carmustine—lymphatic system cancer	0.000488	0.001	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000482	0.00099	CcSEcCtD
Bicalutamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000473	0.000972	CcSEcCtD
Bicalutamide—Dysuria—Methotrexate—lymphatic system cancer	0.00047	0.000966	CcSEcCtD
Bicalutamide—Neutropenia—Methotrexate—lymphatic system cancer	0.00047	0.000966	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000469	0.000964	CcSEcCtD
Bicalutamide—Abdominal pain—Vincristine—lymphatic system cancer	0.000466	0.000957	CcSEcCtD
Bicalutamide—Body temperature increased—Vincristine—lymphatic system cancer	0.000466	0.000957	CcSEcCtD
Bicalutamide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000463	0.000951	CcSEcCtD
Bicalutamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000456	0.000937	CcSEcCtD
Bicalutamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000455	0.000934	CcSEcCtD
Bicalutamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000453	0.000932	CcSEcCtD
Bicalutamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000453	0.000932	CcSEcCtD
Bicalutamide—Pneumonia—Methotrexate—lymphatic system cancer	0.000451	0.000926	CcSEcCtD
Bicalutamide—Vomiting—Bleomycin—lymphatic system cancer	0.000449	0.000924	CcSEcCtD
Bicalutamide—Depression—Methotrexate—lymphatic system cancer	0.000447	0.000918	CcSEcCtD
Bicalutamide—Rash—Bleomycin—lymphatic system cancer	0.000446	0.000916	CcSEcCtD
Bicalutamide—Dermatitis—Bleomycin—lymphatic system cancer	0.000445	0.000915	CcSEcCtD
Bicalutamide—Asthenia—Carmustine—lymphatic system cancer	0.000443	0.00091	CcSEcCtD
Bicalutamide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000436	0.000895	CcSEcCtD
Bicalutamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000434	0.000892	CcSEcCtD
Bicalutamide—Sweating—Methotrexate—lymphatic system cancer	0.00043	0.000883	CcSEcCtD
Bicalutamide—Haematuria—Methotrexate—lymphatic system cancer	0.000427	0.000878	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000424	0.000871	CcSEcCtD
Bicalutamide—Epistaxis—Methotrexate—lymphatic system cancer	0.000423	0.000869	CcSEcCtD
Bicalutamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000423	0.000869	CcSEcCtD
Bicalutamide—Asthenia—Vincristine—lymphatic system cancer	0.000423	0.000869	CcSEcCtD
Bicalutamide—Diarrhoea—Carmustine—lymphatic system cancer	0.000422	0.000868	CcSEcCtD
Bicalutamide—Nausea—Bleomycin—lymphatic system cancer	0.00042	0.000863	CcSEcCtD
Bicalutamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000412	0.000846	CcSEcCtD
Bicalutamide—Dizziness—Carmustine—lymphatic system cancer	0.000408	0.000839	CcSEcCtD
Bicalutamide—Haemoglobin—Methotrexate—lymphatic system cancer	0.000404	0.000831	CcSEcCtD
Bicalutamide—Diarrhoea—Vincristine—lymphatic system cancer	0.000403	0.000828	CcSEcCtD
Bicalutamide—Haemorrhage—Methotrexate—lymphatic system cancer	0.000402	0.000827	CcSEcCtD
Bicalutamide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000399	0.000821	CcSEcCtD
Bicalutamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000397	0.000817	CcSEcCtD
Bicalutamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000394	0.00081	CcSEcCtD
Bicalutamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000392	0.000807	CcSEcCtD
Bicalutamide—Vomiting—Carmustine—lymphatic system cancer	0.000392	0.000806	CcSEcCtD
Bicalutamide—Dizziness—Vincristine—lymphatic system cancer	0.00039	0.000801	CcSEcCtD
Bicalutamide—Rash—Carmustine—lymphatic system cancer	0.000389	0.0008	CcSEcCtD
Bicalutamide—Dermatitis—Carmustine—lymphatic system cancer	0.000389	0.000799	CcSEcCtD
Bicalutamide—Visual impairment—Methotrexate—lymphatic system cancer	0.000388	0.000797	CcSEcCtD
Bicalutamide—Headache—Carmustine—lymphatic system cancer	0.000387	0.000794	CcSEcCtD
Bicalutamide—Vomiting—Vincristine—lymphatic system cancer	0.000375	0.00077	CcSEcCtD
Bicalutamide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000373	0.000767	CcSEcCtD
Bicalutamide—Rash—Vincristine—lymphatic system cancer	0.000371	0.000763	CcSEcCtD
Bicalutamide—Dermatitis—Vincristine—lymphatic system cancer	0.000371	0.000763	CcSEcCtD
Bicalutamide—Headache—Vincristine—lymphatic system cancer	0.000369	0.000758	CcSEcCtD
Bicalutamide—Nausea—Carmustine—lymphatic system cancer	0.000367	0.000753	CcSEcCtD
Bicalutamide—Angiopathy—Methotrexate—lymphatic system cancer	0.000365	0.00075	CcSEcCtD
Bicalutamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000365	0.00075	CcSEcCtD
Bicalutamide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000363	0.000747	CcSEcCtD
Bicalutamide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000363	0.000745	CcSEcCtD
Bicalutamide—Rash—Mitoxantrone—lymphatic system cancer	0.000362	0.000743	CcSEcCtD
Bicalutamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000361	0.000743	CcSEcCtD
Bicalutamide—Chills—Methotrexate—lymphatic system cancer	0.000361	0.000742	CcSEcCtD
Bicalutamide—Headache—Mitoxantrone—lymphatic system cancer	0.000359	0.000739	CcSEcCtD
Bicalutamide—Alopecia—Methotrexate—lymphatic system cancer	0.000355	0.000731	CcSEcCtD
Bicalutamide—Mental disorder—Methotrexate—lymphatic system cancer	0.000352	0.000724	CcSEcCtD
Bicalutamide—Malnutrition—Methotrexate—lymphatic system cancer	0.00035	0.00072	CcSEcCtD
Bicalutamide—Nausea—Vincristine—lymphatic system cancer	0.00035	0.000719	CcSEcCtD
Bicalutamide—Nausea—Mitoxantrone—lymphatic system cancer	0.000341	0.0007	CcSEcCtD
Bicalutamide—Back pain—Methotrexate—lymphatic system cancer	0.000339	0.000696	CcSEcCtD
Bicalutamide—Anaemia—Methotrexate—lymphatic system cancer	0.000324	0.000665	CcSEcCtD
Bicalutamide—Cough—Methotrexate—lymphatic system cancer	0.000306	0.000628	CcSEcCtD
Bicalutamide—Myalgia—Methotrexate—lymphatic system cancer	0.000298	0.000613	CcSEcCtD
Bicalutamide—Chest pain—Methotrexate—lymphatic system cancer	0.000298	0.000613	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000296	0.000609	CcSEcCtD
Bicalutamide—Confusional state—Methotrexate—lymphatic system cancer	0.000288	0.000592	CcSEcCtD
Bicalutamide—Infection—Methotrexate—lymphatic system cancer	0.000284	0.000584	CcSEcCtD
Bicalutamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00028	0.000576	CcSEcCtD
Bicalutamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00028	0.000575	CcSEcCtD
Bicalutamide—Skin disorder—Methotrexate—lymphatic system cancer	0.000278	0.000571	CcSEcCtD
Bicalutamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000276	0.000568	CcSEcCtD
Bicalutamide—Anorexia—Methotrexate—lymphatic system cancer	0.000272	0.00056	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00026	0.000535	CcSEcCtD
Bicalutamide—Insomnia—Methotrexate—lymphatic system cancer	0.000258	0.000531	CcSEcCtD
Bicalutamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000257	0.000527	CcSEcCtD
Bicalutamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000255	0.000524	CcSEcCtD
Bicalutamide—Somnolence—Methotrexate—lymphatic system cancer	0.000254	0.000522	CcSEcCtD
Bicalutamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000252	0.000517	CcSEcCtD
Bicalutamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000248	0.000511	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000247	0.000507	CcSEcCtD
Bicalutamide—Fatigue—Methotrexate—lymphatic system cancer	0.000246	0.000506	CcSEcCtD
Bicalutamide—Pain—Methotrexate—lymphatic system cancer	0.000244	0.000502	CcSEcCtD
Bicalutamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000236	0.000484	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000234	0.00048	CcSEcCtD
Bicalutamide—Urticaria—Methotrexate—lymphatic system cancer	0.000227	0.000467	CcSEcCtD
Bicalutamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000226	0.000464	CcSEcCtD
Bicalutamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000226	0.000464	CcSEcCtD
Bicalutamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000211	0.000433	CcSEcCtD
Bicalutamide—Asthenia—Methotrexate—lymphatic system cancer	0.000205	0.000421	CcSEcCtD
Bicalutamide—Pruritus—Methotrexate—lymphatic system cancer	0.000202	0.000416	CcSEcCtD
Bicalutamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000196	0.000402	CcSEcCtD
Bicalutamide—Dizziness—Methotrexate—lymphatic system cancer	0.000189	0.000388	CcSEcCtD
Bicalutamide—Vomiting—Methotrexate—lymphatic system cancer	0.000182	0.000373	CcSEcCtD
Bicalutamide—Rash—Methotrexate—lymphatic system cancer	0.00018	0.00037	CcSEcCtD
Bicalutamide—Dermatitis—Methotrexate—lymphatic system cancer	0.00018	0.00037	CcSEcCtD
Bicalutamide—Headache—Methotrexate—lymphatic system cancer	0.000179	0.000368	CcSEcCtD
Bicalutamide—Nausea—Methotrexate—lymphatic system cancer	0.00017	0.000349	CcSEcCtD
